Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,336
Out of 5,182 analysts
135
Total ratings
53.7%
Success rate
31.86%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $24.80 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $70.13 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $731.77 | +16.16% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.64 | +997.56% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $0.58 | +10,207.51% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $3.48 | +158.62% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $5.46 | +522.71% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $183.38 | +78.32% | 7 | Oct 15, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $430.14 | -34.67% | 5 | Jun 11, 2021 | |
| AKBA Akebia Therapeutics | Initiates: Overweight | $8 | $1.42 | +463.38% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.30 | +7,438.46% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $339.57 | -13.13% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $129.26 | -33.47% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $34.58 | +38.81% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $4.69 | +539.66% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $24.80 | +190.32% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $1.58 | +216.46% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $97.74 | +2.31% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $222.08 | -9.49% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $70.26 | +20.98% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $16.04 | +99.50% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $21.07 | +929.90% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $66.11 | -27.39% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $15.22 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $302.11 | -49.03% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $53.30 | +117.64% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $7.54 | +1,305.84% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $13.20 | +112.12% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $196.51 | -58.27% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $569.11 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.03 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $24.80
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $70.13
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $731.77
Upside: +16.16%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.64
Upside: +997.56%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $0.58
Upside: +10,207.51%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $3.48
Upside: +158.62%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $5.46
Upside: +522.71%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $183.38
Upside: +78.32%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $430.14
Upside: -34.67%
Akebia Therapeutics
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.42
Upside: +463.38%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.30
Upside: +7,438.46%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $339.57
Upside: -13.13%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $129.26
Upside: -33.47%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $34.58
Upside: +38.81%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $4.69
Upside: +539.66%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $24.80
Upside: +190.32%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $1.58
Upside: +216.46%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $97.74
Upside: +2.31%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $222.08
Upside: -9.49%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $70.26
Upside: +20.98%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $16.04
Upside: +99.50%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $21.07
Upside: +929.90%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $66.11
Upside: -27.39%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $15.22
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $302.11
Upside: -49.03%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $53.30
Upside: +117.64%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $7.54
Upside: +1,305.84%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $13.20
Upside: +112.12%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $196.51
Upside: -58.27%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $569.11
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.03
Upside: -